Hiroyoshi Taniguchi

1.3k citations

27 papers · 1.1k indexed · h-index 18

Co-authors: Motoyuki Otsuka Masao Omata Naoya Kato Masaru Moriyama Takao Kawabe Tadashi Goto Yasushi Shiratori Yujin Hoshida
Topics: Hepatitis C virus research (13 papers)Hepatitis B Virus Studies (9 papers)Hepatocellular Carcinoma Treatment and Prognosis (5 papers)
Cited by: Hepatology Immunology Cancer Research
Journals: Gastroenterology Hepatology Clinical Cancer Research
Partner nations: Japan United States Israel

In The Last Decade

Hiroyoshi Taniguchi

26 papers receiving 1.1k citations

Peers

Countries citing papers authored by Hiroyoshi Taniguchi

Since Specialization

Citations

This map shows the geographic impact of Hiroyoshi Taniguchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroyoshi Taniguchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroyoshi Taniguchi more than expected).

Fields of papers citing papers by Hiroyoshi Taniguchi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroyoshi Taniguchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroyoshi Taniguchi. The network helps show where Hiroyoshi Taniguchi may publish in the future.

Co-authorship network of co-authors of Hiroyoshi Taniguchi

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroyoshi Taniguchi. A scholar is included among the top collaborators of Hiroyoshi Taniguchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroyoshi Taniguchi. Hiroyoshi Taniguchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A study on prevention of bleeding complications using lusutrombopag for safe RFA in patients with hepatocellular carcinoma with low platelet counts: prospective observational study 2023 ·BMC Gastroenterology ·(unknown),Takamasa Ohki,(unknown),Takuma Teratani,Shinpei Sato,Shuntaro Obi,Takahisa Sato,Masatoshi Akamatsu,Koji Uchino,Hiroyoshi Taniguchi	0
2	Atezolizumab plus bevacizumab as a second-line treatment after lenvatinib failure 2021 ·Kanzo ·Takamasa Ohki,Mayuko Kondo,Koki Sato,Eriko Goto,Koji Uchino,Takahisa Sato,Yuji Kondo,Hiroyoshi Taniguchi,Masatoshi Akamatsu,Shinpei Sato,Hideo Yoshida,Yukihiro Koike,Shuntaro Obi,(unknown)	1
3	Comparison of standard-dose and half-dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis 2014 ·International Journal of Oncology ·Hiroki Nishikawa,Yukio Osaki,(unknown),Haruhiko Takeda,Kaoru Tsuchiya,Kouji Joko,Chikara Ogawa,Hiroyoshi Taniguchi,Etsuro Orito,Yasushi Uchida,Namiki Izumi	20
4	Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan 2014 ·Journal of Cancer ·Hiroki Nishikawa,Haruhiko Takeda,Kaoru Tsuchiya,Kouji Joko,Chikara Ogawa,Hiroyoshi Taniguchi,Etsuro Orito,Yasushi Uchida,Yukio Osaki,Namiki Izumi,(unknown)	28
5	Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment 2009 ·Liver International ·(unknown),Naoya Kato,Ryosuke Muroyama,Hiroyoshi Taniguchi,Bayasi Guleng,Narayan Dharel,Run–Xuan Shao,Keisuke Tateishi,Amarsanaa Jazag,Takao Kawabe,Masao Omata	5
6	Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus† 2008 ·Hepatology ·Narayan Dharel,Naoya Kato,Ryosuke Muroyama,Hiroyoshi Taniguchi,Motoyuki Otsuka,Yue Wang,Amarsanaa Jazag,Run–Xuan Shao,(unknown),(unknown),Takao Kawabe,Masao Omata	58
7	Interferon-beta is activated by hepatitis C virus NS5B and inhibited by NS4A, NS4B, and NS5A 2007 ·Hepatology International ·Masaru Moriyama,Naoya Kato,Motoyuki Otsuka,Run–Xuan Shao,Hiroyoshi Taniguchi,Takao Kawabe,Masao Omata	28
8	Hepatitis C Virus Core Protein Is a Potent Inhibitor of RNA Silencing-Based Antiviral Response 2006 ·Gastroenterology ·Yue Wang,Naoya Kato,Amarsanaa Jazag,Narayan Dharel,Motoyuki Otsuka,Hiroyoshi Taniguchi,Takao Kawabe,Masao Omata	92
9	Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses† 2005 ·Hepatology ·Motoyuki Otsuka,Naoya Kato,Masaru Moriyama,Hiroyoshi Taniguchi,Yue Wang,Narayan Dharel,Takao Kawabe,Masao Omata	103
10	Large-Scale Search of Single Nucleotide Polymorphisms for Hepatocellular Carcinoma Susceptibility Genes in Patients With Hepatitis C * 2005 ·Hepatology ·Naoya Kato,Guijin Ji,Yue Wang,Masanori Baba,Yujin Hoshida,Motoyuki Otsuka,Hiroyoshi Taniguchi,Masaru Moriyama,Narayan Dharel,Tadashi Goto,Run–Xuan Shao,Tadashi Matsuura,Keisuke Ishii,Shuichiro Shiina,Takao Kawabe,Masaaki Muramatsu,Masao Omata	52
11	Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways 2005 ·Gastroenterology ·Run–Xuan Shao,Motoyuki Otsuka,Naoya Kato,Hiroyoshi Taniguchi,Yujin Hoshida,Masaru Moriyama,Takao Kawabe,Masao Omata	36
12	Vitamin K2 binds 17β-hydroxysteroid dehydrogenase 4 and modulates estrogen metabolism 2005 ·Life Sciences ·Motoyuki Otsuka,Naoya Kato,Tohru Ichimura,Shinya Abe,Yasuo Tanaka,Hiroyoshi Taniguchi,Yujin Hoshida,Masaru Moriyama,Yue Wang,Run–Xuan Shao,Narayan Dharel,Ryosuke Muroyama,Fumihiko Kanai,Takao Kawabe,Toshiaki Isobe,Masao Omata	24
13	Hepatitis C Virus Core Protein and Hepatitis Activity Are Associated through Transactivation of Interleukin‐8 2005 ·The Journal of Infectious Diseases ·Yujin Hoshida,Naoya Kato,Hideo Yoshida,Yue Wang,(unknown),Tadashi Goto,Motoyuki Otsuka,Hiroyoshi Taniguchi,Masaru Moriyama,Fumio Imazeki,Osamu Yokosuka,Takao Kawabe,Yasushi Shiratori,Masao Omata	17
14	Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation 2004 ·Hepatology ·Motoyuki Otsuka,Naoya Kato,Run–Xuan Shao,Yujin Hoshida,Hideaki Ijichi,Yukihiro Koike,Hiroyoshi Taniguchi,Masaru Moriyama,Yasushi Shiratori,Takao Kawabe,Masao Omata	103
15	Hepatitis C virus core protein upregulates transforming growth factor‐β1 transcription 2003 ·Journal of Medical Virology ·Hiroyoshi Taniguchi,Naoya Kato,Motoyuki Otsuka,Tadashi Goto,Hideo Yoshida,Yasushi Shiratori,Masao Omata	103
16	Interleukin-1β gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection 2003 ·Hepatology ·(unknown),Naoya Kato,Yujin Hoshida,Hideo Yoshida,Hiroyoshi Taniguchi,Tadashi Goto,Masaru Moriyama,Motoyuki Otsuka,Shuichiro Shiina,Yasushi Shiratori,Yoichi M. Ito,Masao Omata	146
17	Hepatitis C Virus Core Protein Inhibits Apoptosis via Enhanced Bcl-xL Expression 2002 ·Virology ·Motoyuki Otsuka,Naoya Kato,Hiroyoshi Taniguchi,Hideo Yoshida,Tadashi Goto,Yasushi Shiratori,Masao Omata	57
18	Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells 2002 ·Journal of Gastroenterology ·Yujin Hoshida,Masaru Moriyama,Motoyuki Otsuka,Naoya Kato,Tadashi Goto,Hiroyoshi Taniguchi,Yasushi Shiratori,Naohiko Seki,Masao Omata	8
19	Interferons Specifically Suppress the Translation from the Internal Ribosome Entry Site of Hepatitis C Virus through a Double‐Stranded RNA–Activated Protein Kinase–Independent Pathway 2002 ·The Journal of Infectious Diseases ·Jun Kato,Naoya Kato,Masaru Moriyama,Tadashi Goto,Hiroyoshi Taniguchi,Yasushi Shiratori,Masao Omata	20
20	Target Gene Therapy for α-Fetoprotein-Producing Hepatocellular Carcinoma by E1B55k-Attenuated Adenovirus 2001 ·Biochemical and Biophysical Research Communications ·Makoto Ohashi,Fumihiko Kanai,Keisuke Tateishi,Hiroyoshi Taniguchi,Paola A. Marignani,Yoko Yoshida,Yasushi Shiratori,Hirofumi Hamada,Masao Omata	33

About Hiroyoshi Taniguchi

Hiroyoshi Taniguchi is a scholar working on Hepatology, Epidemiology and Cancer Research, having authored 27 papers that have together received 1.1k indexed citations. Recurring topics across this work include Hepatitis C virus research (13 papers), Hepatitis B Virus Studies (9 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). The work is most often cited by research in Hepatology (441 citations), Immunology (251 citations) and Cancer Research (161 citations). Hiroyoshi Taniguchi has collaborated with scholars based in Japan, United States and Israel. Frequent co-authors include Motoyuki Otsuka, Masao Omata, Naoya Kato, Masaru Moriyama, Takao Kawabe, Tadashi Goto, Yasushi Shiratori, Yujin Hoshida, Hideo Yoshida and Narayan Dharel. Their work appears in journals such as Gastroenterology, Hepatology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact